Content area
Full Text
REVIEW OF UNCONVENTIONAL CANCER TREATMENT 714X GETS A BOOST On August 22, Cerbe, Inc, the Canadian company that manufactures and distributes trimethylbicyclonitramineoheptane chloride, or 714X, made good on its promise to submit detailed case histories to the National Cancer Institute's (NCI's) Office of Cancer Complementary and Alternative Medicine (OCCAM). The OCCAM is conducting a scientific review of the therapy through its rigorous Best Case Series program.
Cerbe's move is especially significant because so few cases are actually submitted to...